Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care R-GemOx. Data showed a 60% reduction in the risk of disease progression or death based on U.S.
Key figures
- Drug Name
- Epcoritamab
- Phase Of Trial
- Phase 3
- P value us
- < 0.0001
- P value ex us
- < 0.0001
- Hazard ratio us
- 0.40
- Hazard ratio ex us
- 0.44
- Pfs risk reduction us
- 60%
- Pfs risk reduction ex us
- 56%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.